patrol platform power address unmet need
neurolog initi buy price target
next-gen platform signific therapeut potenti
initi coverag neubas buy rate
month price target per share compani spin-out
world-renown carnegi mellon univers pittsburgh pa went
public via revers merger earlier year neubas develop
novel approach gene silenc interven either dna
rna level specif address rang mutat defect
includ abnorm tandem repeat expans singl nucleotid
polymorph compani platform broad applic
view sinc util peptide-nucl acid pna construct
achiev accomplish use standard antisens
oligonucleotid aso properti includ blood-
brain barrier bbb penetr system distribut tissue-specif
target single-bas allel sensit neubas deep
pipelin two advanc initi
huntington diseas hd myoton dystrophi type
case program could constitut mini-pipelin
sinc could appli array
orphan diseas beyond neubas focus
parkinson diseas pd well hitherto undrugg target
oncolog arena
develop pathway high-valu indic believ
neubas could benefit rel spars competit
landscap orphan central nervou system indic like hd
may permit achiev regulatori
approv base small target clinic trial hd exampl
histor preced indic approv base singl phase
trial patient singl phase studi subject
note hd orphan ultra-orphan natur
anticip total address patient popul roughli
individu hd alon premium price
ought achiev view given chronic debilit
natur diseas preced set drug like nusinersen
spinal muscular atrophi sma therefor assum price
per patient hd per patient
program could thu reach blockbust statu
alon vieww project peak sale
expect initi clinic data
program note preclin
proof-of-concept result key experiment model becom
avail candid next year
multipl strateg option monet platform strength
believ mani strateg entiti could look neubas order
revit intern drug develop effort given broad-
base util patrol technolog feel would
emin possibl neubas develop commerci
independ given natur focus market
much like trend-set compani alnylam ioni view
neubas platform compani could also develop launch
proprietari product
definit distribut analyst rate analyst certif disclosur pleas refer page report
valuat risk valu neubas use discount cash flow dcf -base analysi yield total firm
valu base alon assumpt includ probabl launch
probabl launch also appli discount rate termin growth rate
effect tax rate employ risk includ limit inabl advanc
clinic develop failur gener posit clinic data hd inabl
valid technolog platform high-profil partnership licens transact failur secur regulatori
approv potenti near-term dilut risk
neubas emerg biotech compani develop next-gener gene silenc
therapi aim cure rare diseas genet origin address high-valu histor
undrugg oncolog target base pittsburgh pa neubas found went public
via revers merger ohr pharmaceut inc juli concomit
revers merger neubas complet million privat placement subsequ
supplement million invest greenlight capit led well-known fund manag
david einhorn greenlight current estim roughli neubas outstand share
neubas uniqu view lie expertis design next-gener antisens
oligonucleotid aso combin focu develop potenti cur agent rare diseas
genet origin see figur attract aso platform base abil silenc
disease-caus gene commerci success spinraza nusinersen spinal muscular atrophi
drug gener billion sale valid promis aso
therapeut simultan overlook challeng face therapeut class clinic
test includ degrad endogen nucleas insuffici half-lif unwieldi size
undesir off-target context neubas technolog platforma modular peptide-nucl
acid pna antisens oligonucleotid construct patrol appeal us patrol
shown abil silenc diseas gene also potenti overcom
aforement challeng base result obtain preclin test also emphas myriad
uniqu advantag patrol includ rapid drug design select blood-brain barrier bbb
penetr target genom dna double-strand rna potenti system distribut
tissue-specif target single-bas allel sensit
genet diseasesth major affect nervou systemar caus repeat
expans nucleotid includ so-cal trinucleotid expans repeat tnr repres
market opportun total sever billion dollar annual wherein approv treatment current exist
view neubas slate captur signific portion larg untap market
proprietari patrol technolog abil bind sequest disease-caus nucleic acid
sequenc evok gene silenc instanc case huntington diseas hd mutat
version htt gene huntingtin gene carri cytosine-adenine-guanin
trinucleotid repeat compar repeat wild-typ wt gene result
schoch miller neuron
product disease-caus huntingtin neubas shown platform power
mitig possibl block expand repeat caus patholog fact repeat
implic least diseas provid scope neubas appli platform technolog
across multipl indic collect repres lucr neubas receiv exclus
world-wide licens patrol technolog platform carnegi mellon univers cmu world-
lead academ institut base pittsburgh pa strateg neubas intend focu treat
rare neurodegen diseas express tnr retain central nervou system -specif
usag right platform explor busi partnership advanc util technolog
therapeut area clinic develop front neubas aim advanc two lead
clinic evalu hd
associ abnorm level repeat develop myoton dystrophi type
express abnorm ctg repeat expect neubas focu addit area
come month includ domin genet disord oncogen mutat
neubas found pittsburgh pa
revers merger ohr pharmaceut close neubas list
complet privat placement greenlight capit
board director newli reverse-merg neubas announc
danith ly inventor patrol join neubas chief scientif offic
vivo safeti efficaci data
vivo safeti efficaci data
compani report wainwright co
neubas found professor dietrich serv presid ceo prof
previous found co-found sever firm includ navigen person genom
compani part thermofish scientif amnestix biopharma compani focus
improv cognit function part sygni aueon inc cancer diagnost firm silicon valley
biosystem special clia-certifi clinic laboratori focus genet basi human
diseas rebrand lifecod peptilog inc develop short peptid therapeut
base platform patrol platform conceiv reduc practic cmu prof
danith ly neubas chief scientif offic prof ly primari inventor patrol-
relat patent exclus licens neubas former professor harvard medic school
current co-director univers pittsburgh medic center upmc neurolog institut prof
robert friedland serv consult chief medic offic neubas prof georg church
harvard univers veteran genom engin dna sequenc synthet biolog
publish paper co-found biotech firm member neubas scientif
advisori board assist samuel broder former director nation cancer institut nci
also play crucial role develop first three fda-approv agent acquir immun
defici syndrom aid retrovir azt didanosin ddi hivid ddc board
member goldstein diego miral also strong track record dr
goldstein success ventur capitalist also serv board sever biopharma firm
includ biolog cempra pharmaceut part melinta therapeut durata
therapeut part allergan esperion therapeut loxo oncolog part eli lilli
co dr miral ceo vividion johnson johnson veteran
la spada et al annal neurolog
henri paulson handbook clinic neurolog
multifacet platform meld qualiti small molecul antisens peptid drug
recent report publish iqvia rais concern statist roughli
orphan diseas current treatment option see figur within alon million
peopl american affect orphan diseas patient popul
children put perspect global popul may affect orphan diseas
repres million peopl orphan diseas trackabl upon patient
diagnosi infecti diseas birth defect cancer major still elus
fewer orphan medicin approv thank orphan
drug act treatment option increas exponenti see figur defin
characterist orphan drug act includ definit orphan diseas patient
 seven-year market exclus drug sponsor tax incent recoup certain clinic trial
cost financi support engag addit clinic test regulatori incent exempt
fee charg fda
figur orphan drug approv increas exponenti last three decad
light fact orphan diseas genet basi scientif commun
turn attent toward genet mutat associ condit
shed spotlight two type mutat could link diseas progress recess
mutat aris result loss function copi gene domin mutat
occur one copi gene lead either gain- loss-of-funct result protein
lead diseas within context domin mutat two subtyp autosom
domin mutat mutat gene present autosom x-link domin mutat
mutat gene present sex chromosom diseas former categori includ hd marfan
syndrom latter categori fragil syndrom rett syndrom case alport
abil select silenc disease-caus gene use therapeut molecul revolution
field gene silenc context deploy antisens oligonucleotid aso appear
attract therapeut modal aso abil recogn hybrid mrna
watson-crick base pair result inhibit translat even though exact
mechan aso-medi gene silenc still unclear two explan propos
contextu complex process mechan propos sequence-specif bind
aso mrna creat steric hindranc ribosom bind result shut
translat mutat mrna disease-caus protein mechan propos
aso bind mutat mrna partner first step follow degrad mrna transcript
endonucleas ribonucleas rnaaseh non-sequence-specif manner see figur
figur aso silenc gene translat inhibit cleavag mrna transcript
tradit oligonucleotid design bind mrna partner invok gene silenc short
chemic variant dna rna nucleotid length spectacular advanc
field yield hand fda-approv aso drug see figur
figur timelin scientif clinic mileston aso therapi
one major challeng associ aso therapi effici drug deliveri disease-relev
tissu particular phosphodiest backbon present tradit aso suscept cleavag
martinovich et al molecular cellular pediatr
ubiquit enzym nucleas esteras tissu barrier includ blood-brain
barrier bbb pose addit challeng aso reach target insid nucleu
splice take place context neubas patrol platform appear possess multipl
advantag vs exist antisens modal see figur
patrol platform base peptide-nucl acid pna novel class small molecul dna
mimet wherein deoxyribos phosphodiest backbon dna replac pseudo-peptid
backbon unit see figur pna virtu resembl
dna rna possess abil bind hybrid complementari dna rna sequenc
normal watson-crick base-pair high affin sequenc select addit
unnatur peptid backbon present pna render molecul chemic resist
cleavag nucleas virtual littl bind serum protein cellular view
truli set pna apart abil recogn double-strand nucleic acid form either
parallel tripl helix wherein amino end pna align end dna sequenc
strand-invas complex wherein pna molecul displac one dna strand see figur
overleaf pna possess sever peculiar uniqu physicochem properti compar
natur counterpart unnatur backbon pna render charg neutral elimin electrostat
repuls neg effect bind affin caus excel hybrid affin
target sequenc addit outcom pna bind independ medium salt concentr
wherea low ionic strength reduc stabil dnadna duplex also pna show stabil
acid ph ph dna prone depurin lower ph despit attract featur
pna origin fell flat lack certain key physicochem attribut crucial drug
develop exampl pna poor water solubl cellular permeabl due charg
neutral backbon also tend aggreg non-specif manner attempt improv
physicochem attribut pna includ incorpor charg amino acid residu
backbon sequenc replac origin aminoethylglycyl backbon skeleton negatively-
charg scaffold conjug high molecular weight polyethylen glycol one oligom termini
fusion pna dna gener chimer oligom histor met partial
success result reduct bind affin sequenc serv emphas
uniqu neubas platform shown capac solv issu pna
rozner journal nucleic acid
nielson egholm current issu molecular biolog
rozner wainwright co
neubas patrol technolog modularli design address physicochem limit face
pna design incorpor four compon peptid backbon includ unnatur
backbon pre-organ stereoisom engin nucleotid access bind
secondari tertiari structur dna rna cell bbb penetr moieti
self-assembl target rna crucial target repeat expans nucleotid see figur
peptid backbonecel bbb penetr moietyengin nucleotidesself-assembl rnaproteas nucleas resistantnon-polar tighter bind intercal dsdna dsrnapre-organ high bind affin stereoisomersnot immunogen tlr innat adopt act viaster hindranc splice transcript translat etc enabl activ transloc across cell membranesbroad tissu distributiondeliv drug across bbb system administrationlong resid time within cellsincreas select mutant transcript tune h-bondingaccess bind secondari tertiari structur bi-specif janu basesen shorter oligom act like small molecul ad end oligo enabl end-to-end link across targetallow short oligo becom select link togeth provid select expand trinucleotid repeat structuresen catalyt function short oligom neubas therapeut inc
adm
view patrol platform sever compel featur manipul design
person medicin target mrna dna see figur presenc
group molecul afford opportun fine control variou absorpt distribut
metabol excret
pharmacokinet cell permeabl water solubl biocompat tissu distribut clearanc
bbb penetr cytotox incorpor flexibl modular design patrol
platform allow combin best properti small molecul oligo reflect
favor length molecul three nucleotid compar tradit aso
lego-lik capabl presenc recognit element possess tunabl bind affin
specif much like small molecul unnatur peptid backbon resist proteas
nucleas facil synthesi scale-up commerci manufactur shown
contrari convent belief rna molecul easier target protein contain
four build block interact dictat watson-crick base-pair
mere chang recognit element patrol platform one theori select target
mutant mrna implic multipl domin genet view two arena
patrol candid score highli vs small molecul aso sinc secondari
structur rna thermodynam less stabl vs standard double-strand structur dna
rna form single-strand loop bulg site hard access
convent drug discoveri standpoint rapidli evolv site cancer bacteri viral infect pose
signific challeng small molecul aso strikingli patrol platform molecul
given modular formcan access hard-to-target genet element target rapidli
evolv site readili modifi necessari match newly-emerg sequenc
addit silenc rna patrol system silenc gene dna level alter pre-rna splice
activ access variou rna molecul silenc similar pna patrol system
invad dna form triplex complex patrol/dna/patrol via watson-crick hoogsteen
pair displac dna strand neubas perfect patrol platform well next-
gener patrol candid much smaller self-assembl expans transcript
cooper bind sinc molecul bind strongli among
also mutant mrna patrol candid may optim treat nucleotid repeat
expans disord hd
select target engag protein express knock-down function impact
although dna- rna-bas chemic agent includ pna could serv excel chemic
tool studi vitro system hitherto fail impress live experi situ/in vivo
poor cellular uptak henc less prefer context develop antisens
therapi regard impress guanidine-bas peptid nucleic acid gpna
bind mrna high affin sequenc select resist cleavag endonucleas
importantli penetr cellular membran see figur
figur gpna dna mimet stabl possess favor properti
thoma et al wainwright co
incorpor guanidinium function molecul improv cellular uptak novel
concept alreadi shown howev danith ly group
carnegi mellon exploit fullest develop next-gener pna prof ly group
initi show instal rel small hydrophil -diethylen glycol minipeg
r-mp unit -backbon transform randomli fold pna right-hand helix synthesi
optic pure r-mp pna monom could accomplish simpl step commerci
avail rel cheap boc-l-serin synthes r-mp pna oligom
preorgan right-hand helix hybrid dna rna greater affin sequenc
select water solubl less aggreg parent pna order
demonstr potenti gpna design antisens therapeut ly group conduct
preliminari proof-of-concept experi use test case epiderm growth factor receptor egfr
involv growth progress sever type cancer order add credenc
gpna approach see figur overleaf incub head neck squamou cell carcinoma
hnscc non-smal cell lung cancer nsclc cell line egfras-gpna result
reduct efgr mrna protein level thu suggest incorpor guanidin function
wise choic furthermor reduct tumor growth indic gpna effect
penetr cell membran engag egfr target also observ hnscc nsclc
sensit egfras-gpna treatment ascertain dose-depend studi result
specif treatment egfras-gpna display greater growth inhibit vs either
usag scrambl sequenc cell line collect result show
conjug pna cation function guanidium group case power
approach improv cellular uptak otherwis cell-imperm pna view studi also laid
groundwork neubas explor patrol gener next-gener antisens
therapi trigger gene silenc
wender et al proceed nation academi scienc
sahu et al journal organ chemistri
figur egfras-gpna engag intracellular egfr induc cell senesc
tissu specif cell blood-brain barrier permeabl therapeut activ vivo
mani technolog platform histor produc outstand result vitro vivo data appear
mediocr strikingli system administr patrol candid egfras-gpna
xenograft-bear nude mous model hnscc tumor result vivo uptak molecul
tumor within four hour post-inject elicit down-modul egfr level see figur
sinc patrol platform combin improv physicochem characterist
typic present small molecul enhanc resist cleavag improv cellular
uptak select aso therefor built necessari prerequisit system
administr combin capac engag specif target vivo egfr case
potenti imposs achiev unmodifi pna due slow cellular uptak
even interest view power patrol molecul cross blood-brain
barrier accumul brain tissu peak four hour retain antitumor impact
hour base unpublish murin model studi data prof ly group underscor
potenti patrol engag biolog target present brain high degre specif
believ characterist like particular relev given neubas state object
focus neurolog disord
furthermor head-to-head comparison studi involv fda-approv egfr-target drug
patrol candid display antitumor effect compar cetuximab erbitux chimer
anti-egfr monoclon antibodi approv treat metastat colorect cancer metastat nsclc cancer
head neck cancer outperform erlotinib mesyl tarceva small molecul
receptor tyrosin kinas rtk inhibitor design act egfr target approv
treatment nsclc lung pancreat type
figur patrol molecul penetr cellular brain membran
single-bas silenc capabl part disrupt technolog platform
platform abil modul gene express dna rna level single-
base select therebi control flow genet inform profound impact
gene therapi view one area neubas seek access first step
power patrol technolog effect genom modul demonstr utero deliveri
studi wherein nanoparticl np load patrol candid administ either
intraven iv intra-amniot pregnant mice growth surviv result pup
analyz absenc diseas see figur overleaf intriguingli
discern differ term surviv wean pup treat patrol
candid compar untreat anim receiv sham surgeri note mice live
wean display statist differ long-term surviv compar untreat mice
suggest np-mediat utero gene modul use patrol safe addit gross
bodi weight chang observ studi group suggest patrol candid
caus unexpect neg effect even interest view
patrol-tr gestat mice shown achiev success pregnanc result
pup display development abnorm tumor addit anim treatment
group display signific increas level proinflammatori cytokin compar
untreat fetus suggest patrol candid render neg effect cytokine-
mediat immun respons see figur
power patrol bolster find follow-up mous studi wherein iv
deliveri patrol candid embed nanoparticl correct thalassemia inherit blood
disord wherein bodi make abnorm inadequ level hemoglobin specif utero
deliveri np-encapsul pna/dna result significantli higher level hemoglobin compar
observ untreat -thalassem mice note larger dose patrol candid
elev hemoglobin concentr higher level compar seen lower
dose addit reduct reticulocyt immatur red blood cell count
enhanc post-nat surviv surviv compar untreat group suggest
target rapidli divid expand stem cell popul fetal liver use patrol might
correct thalassemia henc afford interest therapeut opportun
figur intraven intra-amniot deliveri patrol effect
one defin attribut patrol molecul particularli compel view
display uncanni abil impact target genet sequenc without perturb off-target
sequenc single-dos administr np-treat tcpna/dna follow deep sequenc analysi
genom dna extract total bone marrow post-nat mice time-point count
day utero np treatment correct target mutat frequenc see
tabl overleaf analysi seven site exhibit partial homolog target bind site
patrol candid reveal undetect mutat frequenc off-target site total off-
target edit frequenc find show patrol molecul highli select
provid abil access rapidli cycl popul hematopoiet stem cell hsc
fetal liver view key implic rel exist modal
tabl gene edit power patroltm highli select target gene locu
top seven mous genom loci partial homolog pna target site -globin intron previous identifi
sequenc indic genom dna total bone marrow cell week post np treatment subject deep
sequenc analysi loci partial homolog well target locu size region sequenc around site
total number amplicon sequenc number amplicon modifi sequenc list
scientist recent thrill emerg gene-edit tool
zinc-fing nucleas zfn transcript activator-lik effector nucleas talen
enabl direct manipul virtual gene divers rang cell type howev remain
linger concern specif gene edit tool case wherein
non-specif edit unplan genom loci prevail norm creation off-target mutat
may trigger pathogen consequ grave concern contrast patrol candid reli
exogen nucleas explain impress off-target gene edit frequenc make use
endogen high-fidel dna repair pathway also protein abil trigger
unintend adapt immun respons wherea patrol-bas edit see tabl
preliminari vivo test shown patrol use either solo combin
approach correct genet disord remain cautiou find
translat bench clinic yet howev feel potenti neubas possibl
deliv best-in-class specif genet modul could high-profil driver long-term upsid
lead program could enter clinic near term rapid path approv
neubas pipelin remain preclinical-stag junctur believ compani
lead program advantag rapid pathway clinic develop could lead
acceler approv sinc huntington diseas hd
myoton dystrophi md type rare neurodegen disord would emphas
lengthi set preced rapid drug develop acceler approv
indic among high-profil exampl spinraza nusinersen exondi
eteplirsen antisense-bas therapeut approv spinal muscular atrophi sma
duchenn muscular dystrophi dmd respect drug approv base small trial
programsin case spinraza double-blind placebo-control studi
exondi princip data set open-label trial enrol boy
predict precis regulatori requir would need met neubas lead
candid obtain approv believ would benefit rapid
develop could includ proceed directli phase phase market author
base singl pivot trial case
scientif commun thought gain traction tradit genet mutat
solid understand mendelian inherit principl wit paradigm shifta new still-
evolv field focus unpreced expans nucleotid repeat caus genet mutat
depend upon whether expans occur non-cod region intron code region exon
result repetit rna sequenc either translat make protein result mutat
non-funct protein also expand repeat form unstabl mutat may
chang size success generationsi even famili phenotyp rang
diseas affect individu vari markedli express vari level repeat first
nine repeat expans identifi trinucleotid repeat henc believ caus
agent neurogenet diseas exampl trinucleotid repeat time
row consid like sign hd onset howev past year sever publish
genet studi shed light tetranucleotid pentanucleotid hexanucleotid
ftd/al even dodecanucleotid thu underscor relev
expand nucleotid repeat pathophysiolog see figur
figur repeat expans nucleotid certain threshold lethal
pink bar repres repeat level normal diseas condit
ascertain figur size abnorm repeat vari
oculopharyng muscular dystrophi opmd spino-cerebellar ataxia type upward one
sever thousand repeat fx also howev complex might look
outset believ expand repeat open excel scientif opportun site-specif
target mutat resid across entir read frame rna see figur
princip challeng howev design therapeut target expand
guy-franck richard trend genet
repeat wild-typ transcript also approach achiev broad organ tissu
distribut amen optim order fit specif need like game changer
abnorm disease-caus repeat could origin multipl organ regard
believ neubas modular patrol platform substanti edg select bind
undisciplin aggreg disease-caus repeat expans nucleotid across tissu
organ self-assembl process repeat grow molecul concaten
grow well also anoth defin featur patrol molecul
tendenc self-degrad find commensur partner contrast off-
target select tradit aso carri grave concern associ aso therapi
figur abnorm repeat expans occur anywher read frame rna
repeat sequenc link indic diseas place schemat appropri gene locat differ size
associ triangl roughli reflect rang repeat expans size diseas repeat actual
intron also promot element
develop
potenti disrupt approach comprehens huntington diseas therapi
hd autosom domin
neurodegen disord character abnorm muscl coordin cognit declin
dementia individu harbor clinic manifest hd usual mid-lif around year
age progress death year diseas onset rare case childhood late-onset
case also occur sinc hd neurodegen diseas character gener shrinkag
brain degener striatum caudat nucleu putamen specif loss effer
medium spini neuron msn hd patient experi multipl layer symptom depend upon
diseas stage early-stag manifest includ minor chang coordin minor chorea
involuntari movement disord difficulti mental plan depress diseas progress
patient experi pronounc chorea depress sharp declin voluntari activ
mental plan advanc case result sever loss motor function accompani
behavior problem perman depend caregiv etiolog hd complex
believ caus expans repeat genet code synthesi amino acid
glutamin triplet seri first exon huntingtin gene htt chromosom fact multitud
disord collect call polyglutamin disord origin due abnorm product
glutamin hd spinocerebellar ataxia sca spinobulbar muscular atrophi sbma
dentatorubral-pallidoluysian atrophi drpla case hd individu
triplet repeat allel hd whatsoev repeat exceed
high hd occur see figur sinc hd autosom domin disord
single-copi mutat htt gene enough caus fact studi shown
invers relationship age hd onset number triplet repeat see figur
although complet hd penetr seen size subset repeat
length rang manifest hd within normal life span
figur abnorm repeat result huntington diseas earli
despit strong invers relationship shown repeat number partial explain
varianc age onset also appear influenc addit environment
genet factor like modifi gene moreov monozygot twin report show
differ clinic symptom suggest epigenet factor tissue-specif variat repeat
due somat instabl may influenc diseas well hd also character
phenomenon anticip age onset tend decreas success gener
due unstabl natur repeat tend increas size particularli pass
male germlin although germlin instabl explain phenomenon anticip
somat instabl propos mechan underli tissu specif diseas
exact mechan via repeat may caus hd remain unclear howev grow bodi
literatur point gain function mutant protein encod htt gene known
huntingtin protein htt express earli embryogenesi onward even though express
ubiquit htt predominantli present neuron present normal level htt play
regul synapt pathophysiolog condit howev htt trigger cascad
divers event ultim result hd see figur overleaf huntingtin kda protein
contain polyglutamin sequenc terminu multipl consensu sequenc call
heat huntingtin elong factor protein phosphatas target rapamycin
repeat import proteinprotein interact htt protein gener found
cytoplasm partial nuclear local recent nuclear local sequenc nl
describ terminu span amino acid interact karyopherin
protein mediat nuclear import nl compris three consensu compon basic-
charg sequenc downstream-conserv arginin proline-tyrosin sequenc
budworth mcmurray method molecular biolog
rosenblatt et al american journal medic genet
jimenez-sanchez et al spring harbor perspect medicin
figur multitud pathogen mechan could contribut hd
would herculean task comment mechan may contribut hd howev
wish assert thatbas preponder scientif clinic evidenceselect
target repeat transcript impact product mutant htt protein ought
name game fact shown use condit knock-out mous model influx
mutant huntingtin protein fragment requir maintain symptom associ hd
blockad express result disappear inclus amelior behavior
addit studi shown aggreg mutant htt protein shown figur
result toxic three differ pathway name polyq toxic format toxic
amyloid-lik structur result aggreg overproduct toxic gain rna function
muscleblind-lik protein sequestr splice regul protein
play pivot role format normal htt protein protein toxic unleash due
product polyq polya poli protein see figur overleaf fact mice express
untransl rcag-repeat develop hd-like behavior mutant huntingtin also
associ brain patholog exampl -synuclein princip compon lewi
bodi parkinson diseas pd found close huntingtin aggreg excess -synuclein
express associ increas mutant huntingtin aggreg overexpress -synuclein
neg effect autophagi convers deplet correl increas
autophagi mous model hd explain crosstalk two sinc
mutant huntingtin autophagi substrat appear function link -synuclein
huntingtin aggreg oppos obviou cross-seed
figur disrupt rna hairpin could potenti treatment choic hd
bifaci recognit reagent contain janu base mppna backbon interfer
hd diseas pathway select target expand ctg repeat adopt imperfect
hairpin structur normal rna structur conclus
determin spectroscop evid suggest molecul bind via strand
figur uniqu design janu base bival h-bond interact
believ signific advantag vs current treatment space key
attribut follow abil bind repeat rna hairpin bival h-bond
interact smaller size small singl triplet-rep unit length henc opportun
scale-up commerci product bi-faci recognit janu base sequence-specif
select see figur abil self-destruct absenc rna partner
current two fda-approv drug avail symptomat treatment hd
function inhibit vesicular monoamin transport protein necessari releas
neurotransmitt axon termin monoamin neuron synapt cleft first drug
xenazin tetrabenazin market prestwick pharmaceut inc part bausch health
approv treatment chorea associ hd second drug austedo
deutetrabenazin market teva pharmaceut industriesi essenti deuter version
xenazin approv replac six hydrogen atom present
xenazin six deuterium heavi hydrogen atom slow rate drug metabol
greater stabil thu decreas dose frequenc improv pharmacokinet profil therebi
improv safeti toler even though drug help manag symptom
diseas hd patient offer cure view hd complex multivari diseas
etiolog molecular pathogenesi still begin understood context
select target abnorm repeat use might substanti step forward
potenti transform treatment myoton dystrophi diseas
neubas second key asset current develop treatment myoton
dystrophi type abbrevi dm latin phrase dystrophia myotinica highli
degen muscular condit affect everi individu world-wide genet diseas
character progress muscl wast weak caus individu experi
prolong muscl contract myotonia secondari symptom includ cataract cloud
len eye abnorm heartbeat-rel electr signal detail list symptom
occur variou stage shown see figur sometim call steinert diseas
affect differ region bodi includ face neck lower arm leg due
autosom domin natur diseas chanc offspr inherit diseas
parent two form adult form congenit form sever
form wherein present sinc birth characterist featur congenit myoton dystrophi
includ weak muscl tone hypotonia inward- upward-turn foot clubfoot breath problem
delay develop intellectu disabl health problem life-threaten
interestingli myoton dystrophi pass one gener next disord gener
begin earlier life sign symptom becom sever phenomenon call anticip
report type myoton dystrophi howev evid anticip appear
strongest form anticip caus increas length unstabl
region dmpk gene current treatment candid clinic test
figur size ctg repeat affect sever
etiolog convolut still research howev believ caus
expans ctg repeat region dystrophia myotonica protein
kinas dmpk gene respons produc protein call myoton dystrophi protein kinas
dmpk healthi peopl carri five ctg repeat consid normal rang dmpk gene
wherea patient repetit length vari allud abnorm
expans nucleotid repeat code region exon lead alter protein function wherea
occur noncod region intron trigger toxic gain rna function result
diseas without protein sequenc perturb mutat dmpk gene present intron
region chromosom caus toxic mrna adopt unusu imperfect hairpin structur see
figur result rcugexp sequest form binari complex
get trap insid nucleu format binari complex prevent export
cytoplasm result decreas product dmpk key protein necessari
maintain muscl coordin also hamper execut normal physiolog
function termin differenti neuron myocyt
figur abnorm expans ctg repeat contribut phenotyp
effort preclud format toxic binari complex depict figur thu
prevent halt potenti cure neubas elect target abnorm rcugexp transcript
would releas without interf wild-typ benign repeat view fine
control unpreced genet diseas therapi offer uniqu way address condit
caus abnorm nucleotid repeat thu consid neubas technolog platform highli
differenti regard design bind abnorm rcugexp repeat sequence-
specif manner thu preclud format toxic binari complex
competit bind assay denot origin paper abl distinguish
pathogen mrna repeat wild-typ form bind strongli former repeat
mateos-aierdi et al frontier age neurosci
figur demonstr potenti disrupt diseas pathway
interestingli control probe singl base-pair mismatch version display bind
affin whatsoev suggest abnorm rcugexp repeat affin toward
mismatch analogu bind abnorm rcugexp repeat show littl
bind wild-typ form slate accomplish two function name liber
critic product good protein dmpk ablat toxic mrna gain
function conceiv result verifi clinic test would open new
avenu mitigationand possibl reversalof symptom follow-up gel-shift assay
experi addit increas dose system contain rcugexp
result format duplex denot heteroduplex
also disrupt complex see figur right suggest
could cur state earlier congenit sever form present sinc birth
result sever weak problem associ suckl feed breath newli born
babi prove effect congenit set via disrupt previous rcugexp
complex believ would posit receiv commun
think like neubas would limit develop respect
lead target indic name hd abnorm expans repeat trigger hd
also seven neuromuscular disord polyq origin includ drpla dentatorubral-
pallidoluysian atrophi sbma spinal bulbar muscular atrophi spinocerebellar ataxia type
spinocerebellar ataxia type machado-joseph diseas spinocerebellar ataxia
type spinocerebellar ataxia type spinocerebellar ataxia type see figur
event emerg success clinic candid hd
high likelihood could consid mini-pipelin potenti recogn
bind expand ctg repeat implic polyq diseas mention share sever
common trait includ subcort cortic atrophi nuclear aggreg similarli
offer promis least two addit indic includ huntington disease-lik
similar hd harbor abnorm ctg repeat consid signific market
opportun two asset repres may consider valu accret neubas
develop candid optim fashion across multipl orphan diseas indic
vantag point key consider fact acceler develop clearli defin
market exclus applic arena premium price would likewis
applic across disord
orr zoghbi annual review neurosci
figur abnorm repeat link multipl neurolog disord
potenti near-term platform valid licens
aso repres one closely-watch drug class biopharma broader role
field gene silenc potenti multi-billion-dollar opportun repres
case point aso therapi spinal muscular atrophi sma drug spinraza nusinersen
origin develop ioni pharmaceut later licens part billion
agreement gener nearli billion revenu past month see figur
tabl view commerci success spinraza valid antisens platform
hard-to-treat indic also set stage futur aso therapi enter compar
under-explor area interestingli hd therapi therapi target
diseas higher global preval everi peopl everi
peopl respect vs sma everi peopl view could
driver long-term upsid neubas given perform spinraza
develop licens commerci
oncolog
develop licens commerci neurolog disord
total valu
futur mileston
develop licens commerci
develop licens commerci neurolog diseas
develop licens commerci
oncolog
licens commerci
liver diseas
futur mileston
mileston
public compani mention compris akcea therapeut rate rate astrazeneca azn rate bayer bayri
rate rate celgen corp celg rate rate janssenpart johnson johnson rate merck co
rate novarti ag nv rate rate roch hold rog sw rate co ltd tkphf rate
compani report wainwright co
ioni pharmaceuticalsbiogen collabor agreement aso therapi out-licens
transact attract industri fact slew deal exist space mani
involv program either early-stag clinic test yet enter clinic see
tabl previou page skyhawk therapeuticsa preclinical-stag privately-held compani focus
discoveri small molecul correct rna splicingi biggest fundrais year date
aso view skyhawk surpris sever level first platform technolog
skystar skyhawk small molecul altern splice rna despit
valid clinic yet alreadi garner high-impact deal big player includ roch takeda
celgen merck second combin valu announc deal total million
cash up-front payment exce billion futur mileston third skyhawk deploy small
molecul target disease-caus rna wherea player field employ either
oligonucleotid modifi version molecul even though head-to-head comparison
neubas skyhawk carri point sinc platform
valid human clinic studi believ neubas also abil attract similarly-
size deal establish player near-term technolog platform uniqu
attribut strong preclin dataset staunch focu rare diseas genet origin
along line also would like remind investor neubas leucine-rich repeat
kinas program focus rare case parkinson diseas pd neurodegen diseas
natur pd character loss dopamin gradual destroy person brain cell
time result loss motor function seen figur pd affect million
patient million global patient estim econom burden billion per year
 current gold standard treatment levodopa view less favor elicit
symptomat relief affect underli patholog diseas progress mild sever
form sever motor complic occur includ increas time durat medic
effect alreadi worn pd symptom reoccur order address pauciti
treatment option research turn altern treatment modal pathway involv
small molecul biolog combat pd see tabl later section
pd space rife multi-level competit see tabl key competitor briefli offer
perspect gene therapy-focus firm arena feel particularli relev
neubas axov gene therapi voyag therapeut worth mention
differenti platform approach yet converg common focal point increas brain
level dopamin wherea axov key asset axo-lenti-pd licens oxford biomedica mid-
deploy harmless adenosine-associ viru carri payload three gene trigger
product three key proteinstyrosin hydroxylas cyclohydrolas aromat l-amino acid
decarboxylas aadc voyag gene therapi asset vy-aadc design suppli aadc
putamen region on-going phase sunrise-pd trial axo-lenti-pd thu far found
well-toler continu improv motor function without seriou advers event treatment
pd patient vy-aadc phase trial meanwhil improv good time without troublesom
dyskinesia hour baselin reduc time hour month baselin
readout trial suggest gene therapi drug could posit influenc
diseas biolog pd patient like result improv overal qualiti life
clinician express interest therapeut impact observ vy-aadc note
may consid clinic meaning mani patient junctur howev unclear
regulatori path approv exist gene therapi approach may improv diseas
biomark without necessarili lead clinic meaning reduct time
altern replenish dopamin concentr grow bodi evid point
genet mutat lead caus inherit sporad form pd account
pd case see figur believ link variou patholog
mechan associ pd includ -synuclein tau inflammatori respons oxid stress
mitochondri dysfunct synapt dysfunct well autophagy-lysosom system denali
therapeut made signific stride small molecul inhibitor program
protein encod gene regul lysosom function recent report phase trial
met clinic object includ inhibit csf exposur evid pathway
engag safeti toler current undergo phase enrol back-up
candid slate begin phase test neubas yet disclos
preclin data pd space note pathway pd substanti de-risk
denali henc present attract market opportun newcom like neubas develop
figur pathway central pd progress
tabl small molecul biolog investig pd treatment
mechan action
well toler without
csf exposur
back-up clinic candid
singl dose axo-lenti-pd improv
motor function without seriou advers
good time hour baselin
reduc time hour baselin
month
reformul version commerci
achiev benefit similar
levodopa elicit anti-
part
public compani mention compris axov gene therapi ltd rate denali therapeut buy
chattopadhyay mitsubishi tanab pharma mtzpi rate buy chattopadhyay
clinicaltri gov wainwright co
neubas reli upon combin patent trade secret proprietari know-how continu
technolog innov advanc util patrol platform develop mrna-
target next-gener oligonucleotid medicin rare genet diseas see tabl overleaf
neubas ip portfolio regard cite exclus world-wid cmu licens agreement
neubas carnegi mellon univers cmu sign decemb agreement
grant unlimit world-wid right neubas respect patrol technolog associ
patent cover composit matter field use platform long certain mileston
product develop met practic term confer protect janu base well
treatment repeat expans disord use technolog return neubas issu
share common stock cmu addit offer one-tim payment cover
ip-rel cost associ patrol technolog go forward neubas oblig
pay royalti cmu low single-digit percentag aggreg annual net sale licens product
percentag higher rang bottom third sub-licens fee provid neubas
license abl success commerci patrol molecul
neubase-cmu agreement slate expir year effect date expir date
last-to-expir patent licens whichev come later assum around addit cmu
also sever patent-pend applic could extend protect beyond
take account possibl impact hatch-waxman term extens geograph
restrict aris cmu agreement see world-wide patent extens key driver
futur long-term revenu stream particularli sinc rare natur mani genet diseas
could allow orphan design expedit clinic develop regulatori review seven-
year market exclus window ought deter gener competit note patent cover
applic patrol technolog hd one cover wo-
particularli import drug approv approv
therapi delay halt diseas progress exist indic also cmu and/or
neubas could erect addit layer protect includ drug formul rout deliveri
method-of-us claim could increas patent life key therapeut modal
gpna oligonucleotid antitumor agent
template-direct -pna synthesi process
method synthesi use therefor
dival nucleobas compound use therefor
bival nucleic acid ligand use therefor
dival nucleobas compound use therefor
 patent trademark offic uspto neubas therapeut
particular egfra gpna oligonucleotid
util treat malign tumor
invent describ method produc gamma
overcom three major hurdl encount
antisens therapi scale cost cellular deliveri
non-specif bind
invent describ prepar chiral pna
gamma peptid nucleic acid monom well
method detect specif nucleic acid
invent describ novel dival nucleobas
use target double-strand nucleic acid
includ rna secondari structur
invent describ hydrophil pna moieti
improv hybrid properti water solubl
biocompat also invent relat design
synthesi use hydrophil -minipeg pna unit
polyethyleneglycol minipeg mp sidechain
-carbon pna backbon
invent describ bival nucleobas bind
two strand nucleic acid expand repeat
sequenc associ huntington diseas
compris termin aromat moieti bind specif
templat nucleic acid concaten also provid
method use molecul treat diagnos
repeat expans disord
uniqu enabl bind manipul
difficult-to-access doubl helix genom dna
secondari structur rna
model futur sale two neubas pipelin huntington diseas
hd myoton dystrophi type investor note focus sole
potenti candid within market project could occur
territori ex-u furthermor includ assumpt regard neubas
pipelin initi sinc much earlier-stag yet reach point lead
identif yet vantag point orphan indic neubas target
advantag still essenti green field opportun
exist treatment modal either sub-optim well symptomat natur hd
essenti non-exist hd believ particular potenti benefit util
patrol-bas therapeut would abil target system patholog outsid sinc
put therapeut agent could deliv system would substanti advantag
modal cns-restrict natur must deliv use cumbersom rout
pre-symptomat administr mutant gene-carri individu may delay diseas onset
mitig sever progress
price difficult topic tackl current polit environ drug meaning
clinic benefit well cur potenti confid market continu
increasingli underpin compar effect
pharmacoeconom benefit analys recent case spinraza nusinersen price
first year per patient annual subsequ yearsand zolgensma
onasemnogen abeparvovec-xioi price million payabl via annual instal
five-year periodmer underscor natur price paradigm highli impact
therapeut congenit chronic genet disord variou exampl ultra-high price
drug exist firdaps approv ultra-orphan diseas known
lambert-eaton myasthen syndrom lem price suppli tablet
annual basi per patient thu feel price assumpt per
patient annual hd per patient annual reason
view justifi candid perform accord expect shown
orphan drug price larg link diseas preval
nation institut neurolog disord stroke wainwright co estim
nation institut neurolog disord stroke wainwright co estim
huntington huntington address penetr patient administ per patient sale dystrophi type penetr penetr patient administ per patient sale neubas therapeut inc
employ discount cash flow dcf -base approach valu neubas share
assess reli upon forecast sale two compani candid name
huntington diseas hd expect could potenti launch
could gener peak sale billion base peak market share roughli
 alon approxim patient therapi price drug averag
per patient annual estim assum neubas would launch independ
sole commerci drug assum ex-u sale product may
prove conserv forecast assum probabl launch reflect
compound current statu late-stag preclin develop project potenti
regulatori approv commerci treatment congenit adult patient
translat peak sale potenti billion alon price assumpt
substanti higher vs given pauciti treatment option patient
project price start per patient annual peak market penetr
pediatr popul adult popul translat total roughli
patient treatment peak sinc earlier stage develop
ascrib probabl launch agent base assess
sole revenu current factor potenti revenu partnership distribut
arrang outsid territori may prove conserv
tabl composit analysi dcf
conserv use discount rate consid appropri given rel earli
stage develop consid broader uncertainti around drug
price howev consid innov natur program sever unmet
medic need hd rel small patient popul involv confid
premium price level project could attain appli termin growth
rate given breadth applic patrol technolog platform may yield multipl
addit pipelin program across rang diseas indic appli tax rate
sum period termin cash flow million equat total firm valu given
lack outstand debt translat price object approxim per share
assum total roughli million share outstand end-fisc assum exercis
million outstand option exercis option issu juli
ten-year term also assum issuanc million share per share earli
neubas inc mm except amount per valu firm debt end-fisc valu firm per shareproduct namelaunch yearpeak salesprob launchnpv neubas inc
fiscal year capit work capit depreci net debt-fre factor net debt-fre ratedcf assumptionsdiscount growth growth factor termin valueperiod neubas therapeut inc
review outlook
revenu forecast revenu gener least manag
provid guidanc
gross margin gross margin compani self-commerci patrol platform-bas
product could exceed gross margin royalty-bas licens revenu slate
oper expens project total oper expens million fiscal consist
million spend approxim million cost fiscal expect
expenditur rise million spend almost doubl million base
forecast assumpt develop cost like rise substanti come
year compani lead candid advanc clinic test
tax decemb compani total estim net oper loss carry-forward
nol approxim million may use off-set futur taxabl incom project
futur revenu tax effect rate base statutori feder corpor incom
tax rate pennsylvania state statutori corpor incom tax rate conserv
assum off-set futur taxabl incom nol sinc compani product
recent revers merger may elig util prior nol base chang control
share count august compani roughli million share common stock
outstand compani also roughli million stock option warrant share
restrict common stock compani may need rais addit capit within next sever
ep forecast compani dilut net loss per share fiscal fiscal
balanc sheet august compani roughli million cash equival
debt expect exist cash resourc suffici fund oper mid-calendar
flow project compani oper would cash flow-neg next sever
year compani may turn cash flow-posit either late earli driven princip
 sale huntington diseas myoton dystrophi type
therapeut modal risk neubas therapeut focus effort peptide-nucl acid pna
technolog discov drug unmet medic need howev class therapeut molecul
repres underexplor area approv drug current market
financi outlook neubas unprofit sinc incept may requir addit capit
futur order drive clinic develop flagship product well candid
thu compani stock could experi above-averag risk volatil
regulatori risk market entri author depend upon success review regulatori
agenciesthes includ entiti food drug administr fda
european medicin agenc ema neubas like view take advantag
orphan design pathway expedit approv candid guarante
product candid advanc neubas satisfi regulatori requir regulatori file
commerci risk guarante drug product neubas approv
success addit though feel pna excit innov standpoint
absolut certainti anoth therapi current develop might prefer
physician detriment neubas product sale may lead neubas profit may
differ materi project gener consensu estim may implic
price stock
competit landscap investig drug candid develop neubas
competit drug either alreadi approv current clinic test within
context huntington diseas hd neubas program may compet market drug
xenazin tetrabenazin austedo deutetrabenazin market bausch health
biopharmaceut compani base barcelona spain develop beta blocker drug
shown inhibit target manner similar seen tetrabenazin
deutetrabenazin roch begun phase test gene-silenc agent design hd
uniqur given clearanc start clinic test viral-bas gene therapi approach
hd well neubas may also face competit parkinson diseas pd arena
multipl market drug well gene therapi compani axov gene therapi axo-lenti-
pd vy-aadc
partnership risk neubas may reli partner manufactur distribut product
insid outsid assur given partner would abl market
neubas product effect neubas could establish new collabor agreement
accept term furthermor neubas may face advers develop partnership
front base decis partner may take strateg reason
intellectu properti risk neubas reli patent trade secret protect product
competit patent protect neubas product method use slate expir
time frame competit rife extrem case may lead lawsuit pursuit
protect intellectu properti guarante neubas parti litig
would prevail potenti oppon
industri risk secur issu emerg healthcar compani inher volatil
increasingli subject develop regulatori risk meet miss develop commerci
mileston may result chang percept firm stock price anticip
volatil subsid near term
addit risk consider pleas refer compani sec file
public compani mention report
akcea rate
allergan plc rate
rate
astrazeneca plc azn rate
axov gene therapi ltd rate
bayer bayri rate
celgen corp celg rate
 co rate
rate
johnson johnson rate
merck co rate
novarti ag nv rate
rate
roch hold rog sw rate
co ltd tkphf rate
teva pharmaceut industri ltd teva rate
thousand except per share data
compani report wainwright co estim
revenue- servic revenue- research other- total revenue- expensescost product servic revenue- research sell marketing- gener depreci total gain loss income/expenseinterest realiz loss market securities- income/expense- total invest incom loss provis incom defer incom tax benefit- net net loss per share net loss per share weight averag number share outstand weight averag number share outstand neubas therapeut inc
thousand except per share data
compani report wainwright co estim
asset cash market securities- restrict cash- account receivable- inventories- asset prepaid total current properti intang restrict cash- market securities- total liabil sharehold equitycurr liabilitiesaccount accru expenses- defer revenue- current liabilities- total current defer revenue- long-term liabilities- long-term defer tax liability- total sharehold equitycommon addit paid-in accumul comprehens income- deficit total sharehold total liabil sharehold neubas therapeut inc
tabl neubas therapeut inc nbse histor statement flow financi project
thousand except per share data
compani report wainwright co estim
flow oper activitiesnet adjust stock-bas compensation- stock option warrant amort intang non-cash expense- chang oper asset liabilitiesaccount receivable- inventories- current account defer revenue- liabilities- total chang oper asset flow oper flow invest activitiesinvest ppe- purchas market securities- sale market securities- matur purchas market securities- flow invest activities- flow financ activitiesproce long-term debt- repay asset-back loan- repay short-term note proce issuanc common stock warrants- flow financ net increase/ decreas cash cash effect exchang rate- cash equival begin cash equival end neubas therapeut inc
materi confidenti intend use institut account defin finra rule may also
privileg otherwis protect work product immun legal rule receiv mistak pleas let
us know email repli delet system may copi messag
disclos content anyon integr secur messag guarante internet
 wainwright co llc rate wainwright employ three tier rate system evalu
potenti return risk associ own common equiti share rate firm expect return given
equiti measur rel basi compani sector price object calcul estim
potenti movement price given equiti could reach provid certain target met defin time horizon
price object subject extern factor includ industri event market volatil
market outperform buy common stock compani expect outperform passiv index compris
common stock compani within sector
market perform neutral common stock compani expect mimic perform passiv index
compris common stock compani within sector
market under-perform sell common stock compani expect under-perform passiv index compris
common stock compani within sector
relat compani mention report
invest bank servic includ limit act manager/co-manag underwrit placement
secur act financi advisor and/or provid corpor financ capit markets-rel servic compani
one affili subsidiari within past month
distribut rate tabl octob
 wainwright co llc firm member finra sipc regist broker-deal
raghuram selvaraju ph certifi view express report accur reflect person view
subject secur issuer discuss part compens directli indirectli
relat specif recommend view express research report neither member
household offic director advisori board member compani
none research analyst research analyst household financi interest secur neubas
therapeut inc inc inc inc inc wave life
scienc ltd includ without limit option right warrant futur long short posit
septemb neither firm affili benefici class common equiti secur
neubas therapeut inc inc inc inc inc
neither research analyst firm know reason know materi conflict interest time
public research report
cover research analyst and/or research analyst household financi interest secur
uniqur includ without limit option right warrant futur long short posit
septemb neither firm affili benefici class common equiti secur
uniqur
neither research analyst firm know reason know materi conflict interest time
public research report
research analyst firm and/or research analyst household financi interest secur
bausch health compani inc inc includ without limit option right warrant futur
long short posit
septemb neither firm affili benefici class common equiti secur
bausch health compani inc inc
neither research analyst firm know reason know materi conflict interest time
public research report
research analyst princip respons prepar report receiv compens base upon
specif invest bank servic transact compens base factor includ total revenu profit
firm substanti portion deriv invest bank servic
firm affili receiv compens inc non-invest bank servic
firm affili receiv compens neubas therapeut inc biolog inc bausch
health compani inc inc inc inc inc
invest bank servic within twelv month seek compens compani mention
report invest bank servic within three month follow public research report
firm affili receiv compens uniqur ltd invest bank
servic within twelv month seek compens compani mention report invest
bank servic within three month follow public research report
 wainwright co llc manag co-manag public offer secur uniqur wave life scienc
ltd past month
firm make market neubas therapeut inc inc bausch health compani inc
inc inc inc uniqur inc wave life
scienc ltd date research report
import disclosur chart found disclaim websit http //hcwco bluematrix com/sellside/
